The monoclonal antibody denosumab demonstrates potent antiresorptive effect in the treatment of osteoporosis, conferring benefit for fracture risk and averting bone loss in select oncological situations. The drug must be used without interruption to prevent a rebound effect, according to Dr Tai-Pang Ip, a consultant endocrinologist from Hong Kong who spoke at AFOS 2017 held in Kuala Lumpur, Malaysia.
Bisphosphonate is one of the first-line therapy for treating osteoporosis, but its long-term use should take into account the balance between its antifracture benefit and risk of adverse events such as atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), according to a presentation at the AFOS 2017 Meeting in Kuala Lumpur, Malaysia.
Patients with type 2 diabetes (T2D) may not necessarily have lower trabecular bone scores (TBS) than nondiabetics, a finding that contrasts with that of previous research, according to a study published in a poster at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
The use of functional imaging modalities such as octreotide scintigraphy and 68Ga DOTATATE PET/CT* enhances localization of tumour-induced osteomalacia (TIO), a rare syndrome characterized by bone pain, muscle weakness, and skeletal deformities due to overproduction of the hormone fibroblast growth factor 23 (FGF23), according to data presented at AFOS 2017.
Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.
About one in four men in the Philippines had osteoporosis but many were underdiagnosed, with old age (>70 years), history of fracture, and family history of osteoporosis being the main risk factors of developing the condition, according to a study presented at the AFOS 2017 Annual Meeting.
Elderly patients with osteoporotic vertebral fractures (OVF) should refrain from undergoing highly invasive surgery, but those with no posterior wall mobility or paralysis may benefit from balloon kyphoplasty (BKP) for OVF with posterior vertebral wall damage, according to a study presented at the 5th Scientific Meeting Asian Federation of Osteoporosis Societies (AFOS) 2017 in Kuala Lumpur, Malaysia.
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.